首页 > 文献资料
-
MRSA感染33例临床分析
甲氧西林耐药的金黄色葡萄球菌(methici llinresistant staphylococcus aureus,MRSA)是引起医院获得性感染的主要病因,在第一个耐青霉素霉的β内酰胺酶类抗生素甲氧西林用于临床不久,便在英国发现了世界上首例MRSA[1].目前,MRSA已成为医院获得性感染的常见致病菌之一,且常为多重耐药菌[2],治疗较为困难.本文对我院重症医学科(ICU)检出的33株MRSA进行临床分析,旨在为ICU患者MRSA感染的防治提供参考依据.
-
1 Clinical observationsGaojushen is a novel anti-cancer drug developed by Xiehe Bio-pharmaceutical Company,Shenyang, China. It is prepared and processed from the filtrate of Staphylococcus aureus culture. The active component contained in it has been shown to be a SEC superantigen that is a metabolite of the culture.This superantigen is marked by its ability to stimulate T cells at a high frequency, thereby giving rise to potent cell-mediated immunological responses and producing a large variety of cytokines with the final rsult of apoptosis of tumor cells. The drug was approved for trial prodoction in 1994 by the Center of the State Evaluation and Review of New Drugs,China,and was licenced for marketing by 1996 after finishing the phase III clinical trial.
-
重症监护室老年痴呆MRSA肺部感染的护理体会
耐甲氧西林金黄色葡萄球菌(Methicillin-resistant Staphylococcus aureus,MRSA)是医院感染的重要病原菌之一,由于其致病性强,多重耐药,传播途径广泛,易导致医院感染流行,且病死率较高,成为临床治疗的难点[1].而重症监护室是MRSA医院感染尤其是呼吸道感染的高发区[2].老年痴呆是一种在正常意识下,丧失智能的疾病,其发病隐袭,进展缓慢,以智能障碍为主的慢性进行性疾病.在发达国家,老年痴呆及其并发症已成为第4位死亡原因[3].